{
    "clinical_study": {
        "@rank": "21573", 
        "arm_group": [
            {
                "arm_group_label": "C-PERT", 
                "arm_group_type": "Active Comparator", 
                "description": "45 patients with cancer"
            }, 
            {
                "arm_group_label": "G-PERT", 
                "arm_group_type": "Active Comparator", 
                "description": "65 patients with cancer"
            }
        ], 
        "brief_summary": {
            "textblock": "Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc\n      Pertechnetate in a cyclotron unit.  A study done at the Cross Cancer Institute in 2011 with\n      ten patients using this imaging agent showed that it was safe and produced images with the\n      same pattern as generator produced Pertechnetate.  This study is now being done in larger\n      numbers of patients to again show that the imaging pattern of both agents is the same, and\n      to again demonstrate its safety."
        }, 
        "brief_title": "An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Thyroid Neoplasms", 
            "Head and Neck Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Thyroid Neoplasms", 
                "Head and Neck Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured\n      by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate\n      (G-PERT; from approved commercial source; using qualitative and quantitative clinical\n      imaging biodistribution data."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  thyroid cancer, or\n\n          -  Head and Neck cancer for salivary gland transfer\n\n          -  age 18-79\n\n          -  biochemical parameters < 5x ULN\n\n          -  WBC > 3.0/uL\n\n          -  ANC > 1.5/uL\n\n          -  platelets > 75,000/uL\n\n          -  hemoglobin > 10 g/dL\n\n          -  Karnofsky 50-100\n\n        Exclusion Criteria:\n\n          -  nursing or pregnant females\n\n          -  < 18 or  > 79 Years\n\n          -  uncontrolled asthma\n\n          -  acute iritis\n\n          -  narrow angle glaucoma\n\n          -  previous radiation to head/neck"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747512", 
            "org_study_id": "DX-CPERT-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "C-PERT", 
                "description": "Patients with thyroid and Head and Neck cancer", 
                "intervention_name": "C-PERT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "G-PERT", 
                "description": "Patients with thyroid and Head and Neck cancer", 
                "intervention_name": "G-PERT", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "99mTc Pertechnetate", 
            "thyroidectomy", 
            "thyroid neoplasms"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": {
            "contact": {
                "last_name": "Marg Landon", 
                "phone": "780 432-8751"
            }, 
            "contact_backup": {
                "last_name": "Merlita Lamadrid", 
                "phone": "780 432-8751"
            }, 
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 1Z2"
                }, 
                "name": "Cross Cancer Institute"
            }, 
            "investigator": {
                "last_name": "AJB McEwan, MB", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer", 
        "overall_official": {
            "affiliation": "Department of Oncology, Cross Cancer Institute, Cancer Care, Alberta Health Services", 
            "last_name": "AJB McEwan, MB", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the safety of C-PERT from adverse event data", 
            "safety_issue": "Yes", 
            "time_frame": "5 months"
        }, 
        "source": "AHS Cancer Control Alberta", 
        "sponsors": {
            "collaborator": {
                "agency": "Cross Cancer Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AHS Cancer Control Alberta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}